Seminoma

Summary

Seminoma (MONDO:0003001) is a disease and 20 clinical trials. Top therapeutic interventions include cisplatin, bleomycin, and etoposide phosphate. A subtype of malignant germ cell tumor — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 20

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	seminoma
Mondo ID	MONDO:0003001
MeSH	D018239
DOID	DOID:4440
NCIT	C9309
SNOMED CT	443675005
UMLS	C0036631
MedGen	11371
GARD	0023322
Is cancer (heuristic)	no

Also known as: seminoma · seminoma, malignant · seminoma, pure

Disease family

This is a subtype of malignant germ cell tumor. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › malignant germ cell tumor › seminoma

Related subtypes (12): germinoma, dysgerminoma, extragonadal germ cell cancer, pulmonary artery choriocarcinoma, malignant testicular germ cell tumor, malignant teratoma, malignant childhood germ cell neoplasm, mixed germ cell tumor, vaginal germ cell malignant tumor, malignant germ cell tumor of corpus uteri, malignant germ cell tumor of cervix uteri, malignant germ cell tumor of ovary

Subtypes (2): extragonadal seminoma, testicular seminoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Bleomycin	Phase 3 (in late-stage trials)
Carboplatin	Phase 3 (in late-stage trials)
Cisplatin	Phase 3 (in late-stage trials)
Etoposide	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Durvalumab, Tremelimumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 20.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	9
Not specified	9
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02341989	PHASE3	ACTIVE_NOT_RECRUITING	Adjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
NCT02375204	PHASE3	ACTIVE_NOT_RECRUITING	Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT01887340	PHASE2	RECRUITING	Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
NCT02834013	PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
NCT03158064	PHASE2	ACTIVE_NOT_RECRUITING	Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors
NCT03937843	PHASE2	ACTIVE_NOT_RECRUITING	Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma
NCT04876456	PHASE2	ACTIVE_NOT_RECRUITING	A Phase II Trial of Cabozantinib With Patients With Refractory GCTs
NCT05529251	PHASE2	RECRUITING	De-escalation Study for Stage IIa/IIb < 3 cm Seminoma
NCT06144736	PHASE2	RECRUITING	PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND
NCT01593241	PHASE2	TERMINATED	Therapy De-escalation in Seminoma Stage IIA/B
NCT02272816	PHASE2	COMPLETED	Carboplatin AUC-10 With Early PET Scanning in Metastatic Seminoma
NCT04435756	Not specified	ACTIVE_NOT_RECRUITING	A Study of miRNA 371 in Patients With Germ Cell Tumors
NCT04914026	Not specified	RECRUITING	MicroRNA as Markers in Testicular Cancer
NCT05142982	Not specified	RECRUITING	Radiotherapy vs Observation for Post Chemotherapy Residual Mass in Advanced Seminoma
NCT06133543	Not specified	RECRUITING	Robot-assisted ICG-guided Sentinel Node Biopsy in Testicular Cancer
NCT06309745	Not specified	RECRUITING	THERApy De-escalation for TESTicular Cancer
NCT07498959	Not specified	RECRUITING	Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer
NCT07601672	Not specified	NOT_YET_RECRUITING	PRISTINE Trial: PRoton Beam Therapy In Seminoma - Toxicity INvestigation and Evaluation of Outcome
NCT00705094	Not specified	COMPLETED	Cardiac Function and Cardiovascular Risk Profile in Testicular Cancer Patients
NCT03262207	Not specified	UNKNOWN	Epigenetic Integrity of Spermatozoa in Patients With Germinal Testicular Tumours

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CISPLATIN	4	4
BLEOMYCIN	4	1
ETOPOSIDE PHOSPHATE	4	1
IFOSFAMIDE	4	1
TREMELIMUMAB	4	1